Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving ...

Skovronsky told the outlet that the company is now working to tackle other diseases like Alzheimer’s, neurodegenerative diseases, heart health and even hearing loss. Eli Lilly first launched its ...

Heidi McWilliams, a 10-year Palm Beach resident, is chair of the organization's inaugural event at the Palm Beach County ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

Lilly and AZ have a rival in the BACE field – Merck's MK-8931 is currently in a phase 2/3 study treating patients with mild to moderate Alzheimer's. BACE offers hope ...